Ignite Creation Date:
2024-05-05 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00219193
Status:
COMPLETED
Last Update Posted:
2017-02-07
First Post:
2005-09-12
Brief Title:
A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Valsartan in Hypertensive Non Responders Patients
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
An Eight Week Multicenter Study to Evaluate Efficacy and Safety of the Triple Combo of Aliskiren ValsartanHCTZ 30032025 mg Compared to the Double Combos of AliskirenHCTZ 30025 mg or ValsartanHCTZ 32025 mg in Patients With Essential Hypertension Not Adequately Responsive to HCTZ 25 mg
Status:
COMPLETED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the blood pressure lowering effect and safety of the triple combination aliskiren valsartan HCTZ 30032025 mg in patients with essential hypertension not adequately responsive to HCTZ 25 mg
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None